AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
MANCHESTER, ENGLAND -- Only 7% of patients with inflammatory bowel disease were on appropriate bisphosphonate therapy in a case-control study, Dr. Nigel Arden said during the annual meeting of the British Society for Rheumatology.
Given the high risk for osteoporosis in this group, that percentage should be closer to 100%, said Dr. Arden of the Medical Research Council environmental epidemiology unit at the University of Southampton (England).
At the very least, patients with IBD should be treated with bisphosphonates. They should also receive counseling on lifestyle measures to reduce bone loss and avoid fractures, Dr. Arden said.
Routine bone densitometry scans are appropriate for patients older than 60 years and for those with more severe disease, he added.
Patients eligible for the study were all those registered in the U.K. General Practice Research Database. A total of 231,778 patients were identified as having had a fracture and were compared with 231,778 age- and sex-matched controls with no fractures.
Among those patients with fractures, 1,134 had a history of inflammatory bowel disease (IBD), compared with 896 patients among those without fractures.
IBD patients had a 1.21 adjusted odds ratio for fracturing a hip or vertebrae compared with controls, Dr. Arden said at the meeting.
Source: HighBeam Research, Osteoporosis prevention dismal in patients with IBD. (Only 7% on...